Head-to-head · WeighScore
Ecka Health vs Gala Health
By GLP-1 ScorecardUpdated
Score comparison
Gala Health has the higher recorded score — 82.9/100 to 59.3/100.
Gala Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Gala offers low advertised injection prices and a branded Ozempic path, but its campaign and longer-term plan pages need to be reconciled before paying.
Before you choose
Before comparing the headline prices, the Ecka Health review and the Gala Health review set out the plan length, renewal date and extra fees behind each semaglutide figure in the table below, and the semaglutide cost page compares published rates across the field. A lower starting price can still mean a larger bill once a longer commitment or a separate membership is added.
If neither one fits, Ecka Health vs RxSpan MD and Eclipse Medical Wellness vs Gala Health compare each of them with another graded program, and the list of alternatives to Ecka Health ranks the programs closest to Ecka Health on price, features and score. Those pages, like every entry in the review directory, use the same six graded factors, so the scores carry across.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | Ecka Health | Gala Health |
|---|---|---|
| WeighScore | 59.3/100 | 82.9/100 |
| Grade | C | B− |
| Site position | #376 | #11 |
| Semaglutide | Advertised from $99/mo; pricing shown during the online visit, plan length not published | From $69/mo on the annual plan, billed once a year (campaign shows $129/mo; offers conflict—confirm billing term) |
| Tirzepatide | Advertised from $199/mo; pricing shown during the online visit, plan length not published | From $99/mo on the annual plan, billed once a year (campaign shows $179/mo; offers conflict—confirm term) |
| Coverage | Advertised as nationwide; no state list | Coverage wording differs: all 50 on homepage, most U.S. states in campaign |
| Brand-name access | Yes | Yes |
| Oral / sublingual | Not confirmed | Not confirmed |
Site position #376 · C
Strengths
- Names its prescribing physicians
- Offers brand Zepbound alongside compounded options
- Shows a LegitScript seal
What to consider
- The real price appears only during the online visit
- No legal company name or address is published
- The semaglutide page never says whether the drug is compounded or brand, and the tirzepatide page still shows template placeholder text
- Approved orders are final and not refundable
Strengths
- Campaign advertises $129 semaglutide and $179 tirzepatide with medication and telehealth visits included if prescribed
- Brand-name Ozempic path and broader menopause/HRT services listed
- Terms identify clinical practice networks; actual clinician and pharmacy assignment still need checking
What to consider
- Annual-plan and no-contract campaign presentations differ; the lowest prices are advertised as billed once a year
- Cancel at least 72 hours before renewal; ordinary cancellation does not produce a refund
- Medical-disqualification refund wording differs between full-refund and remaining/current-cycle provisions
- Dispensing pharmacy not identified for an individual order; oral option is a waitlist, not a current offer
Featured provider
Gala Health
Factor scores not reassessed.Gala Health scores 82.9/100 (B−). Gala offers low advertised injection prices and a branded Ozempic path, but its campaign and longer-term plan pages need to be reconciled before paying.
Commercial relationships affect this placement. The score comparison above is separate.
Prices and terms can change; confirm them with the provider. Our factor scores may reflect earlier assessments; see our methodology. Not medical advice; see our disclosure.